The combined effect of SETD2 overexpression with ERG gain or PTEN loss may lead to more aggressive tumor behavior, including increased metastatic potential and resistance to treatment, resulting in poorer prognostic outcomes for patients [29]. The gene discussed is SETD2; the disease is neoplasm.